Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN and DHA-PPQ in children with uncomplicated malaria in Rwanda
NCT04767217Phase 4Completed
- Sponsor
- Jhpiego
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of artemether + lumefantrine and dihydroartemisinin + piperaquine in malaria, sponsored by Jhpiego. Started Jun 2021; status: completed.
02
Drugs
artemether + lumefantrinedihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04767217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767217.